The immunohistochemical profile showed that 50% of women with breast cancer had positive estrogen receptor (ER) and 50% had negative estrogen receptor, and there was a predominance of 56.7% for positive progesterone receptor (PR) and 80% negative for human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast cancer.